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Abstract
Background: We wished to determine if there were differences in pelvic and non-pelvic
tenderness between men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) Type III
and men without pelvic pain.
Methods: We performed the Manual Tender Point Survey (MTPS) as described by the American
College of Rheumatology on 62 men with CP/CPPS Type IIIA and IIIB and 98 men without pelvic
pain. We also assessed tenderness of 10 external pelvic tender points (EPTP) and of 7 internal
pelvic tender points (IPTP). All study participants completed the National Institutes of Health
Chronic Prostatitis Symptom Inventory (NIH CPSI).
Results: We found that men with CPPS were significantly more tender in the MTPS, the EPTPS
and the IPTPS. CPSI scores correlated with EPTP scale but not with IPTP scale or prostate
tenderness. Prostatic tenderness was present in 75% of men with CPPS and in 50% of men without
CPPS. Expressed prostatic fluid leukocytosis was not associated with prostatic tenderness.
Conclusion: Men with CP/CPPS have more tenderness compared to men without CPPS.
Tenderness in men with CPPS is distributed throughout the pelvis and not specific to the prostate.
Background
Idiopathic prostatitis (also called non-bacterial prostati-
tis) and prostatodynia have been renamed by a National
Institutes of Health (NIH) consensus panel to Chronic
Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Types IIIA and IIIB, respectively. These syndromes are
characterized by pelvic pain, a negative prostatic localiza-
tion culture, and no specific diagnosis accounting for the
pain. Voiding symptoms may or may not be present. Type
IIIA is differentiated by leukocytes in the expressed pros-
tatic secretions (EPS) and Type IIIB is characterized by a
lack of inflammation in the EPS [1]. Recently, a large mul-
ticenter study found that the symptoms of prostatitis were
not associated with prostatic inflammation, casting doubt
on prostatic inflammation as the direct cause of the
pain[2].
Pelvic tenderness has not been investigated in normal
men. In CP/CPPS, tenderness of the prostate is often
present [3,4], however its relationship to prostatic inflam-
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ized to the prostate or is part of a more generalized
tenderness has not been determined.
The quantification of tenderness is difficult and subject to
considerable inter-rater variability[5,6]. However, tender-
ness is extremely important in everyday clinical evalua-
tion and is routinely used to identify pathological
processes. The American College of Rheumatology has
developed The Manual Tender Point Survey (MTPS) as a
standardized method to evaluate fibromyalgia (FM)[7].
This instrument includes 18 examination points that are
often tender and 3 control points that are infrequently
tender in patients with FM. Fibromyalgia (FM)is distin-
guished by multiple tender sites and pain in four quad-
rants of the body[8]. Patients with interstitial cystitis (IC),
a condition that may be related to CP/CPPS, have been
found to have increased tenderness in the pelvis and and
in the MTPS as compared with patients without IC[9]. The
purpose of this study was to use the MTPS, expanded to
include pelvic tender points, to test the hypothesis that
men with CP/CPPS would show more overall tenderness
than men without pelvic pain. We hypothesized that the
location of tenderness in CP/CPPS may indicate the loca-
tion of underlying pathology and the extent of the tender-
ness may indicate a localized or more systemic nature of
the syndrome. We explored the relationship of prostatic
secretion inflammation to tenderness. A finding of an
association between prostatic inflammation and prostatic
tenderness would support the possibility that inflamma-
tion produces tenderness and pain. More muscle tender-
ness in men with CP/CPPS IIIB than in men with CP/
CPPS IIIA, as suggested by Segura[10], would support the
continued distinction between the two syndromes. We
also hypothesized that there would be a relationship
between tenderness and CPSI scores.
Methods
Study participants
The University of Washington's institutional review board
approved the study reported here as part of a more com-
prehensive study of men with pelvic pain. All subjects
signed written consents explaining study procedures.
Other findings from the larger study have been reported
previously[11-16]. Patients with CP/CPPS were identified
from the University of Washington Prostatitis Clinic.
Study inclusion criteria for CP/CPPS patients were age
18–65 years, diagnosis of CP/CPPS Type IIIA or IIIB made
by a urologist at the clinic, negative prostatic localization
cultures for pathogens, pelvic pain of at least 3 months
duration, and no other identified pathology to account
for symptoms. Controls were healthy volunteers without
pelvic pain or history of any urologic disease, recruited
from advertisements. Controls were not excluded for the
presence of pain in other areas of the body. Controls were
paid $250.00 for participation in the study, but patients
were not paid. Evaluators were not blinded as to the
patient or control status of the subjects.
Procedures
Patients and controls were evaluated during a screening
visit to the clinic. Study participants were requested not to
take anti-microbial agents within six weeks of examina-
tion and were instructed to abstain from ejaculation for
48 hours prior to their appointment. All subjects provided
demographic information on questionnaires and the NIH
Chronic Prostatitis Symptom Index (CPSI), a measure of
pain severity, urinary symptoms and quality of
life[17,18]. Following a standardized history and physical
examination, patients and controls underwent four-glass
urine localization cultures and urethral cultures for C. tra-
chomatis, U. urealyticum, M. hominis, and T. vaginalis.
Expressed prostatic secretions (EPS) were assessed for leu-
kocyte concentration by hemocytometer counts using a
phase contrast microscope[14]. We defined CP/CPPS
Type IIIB as less than and Type IIIA as more than 500 leu-
kocytes/microliter[11]. Patients and controls were
excluded from further study participation if any of the fol-
lowing conditions were present: active urinary tract infec-
tion or infection localized to the prostate from a four-glass
urine sample, positive cultures for C. trachomatis or N. gon-
orrhoeae, genitourinary malignancy, evidence of suicidal
ideation or psychosis, post-surgical pain, pain from
another source in the genitourinary tract (e.g., renal cal-
culi), history of radiation therapy, or history of genitouri-
nary tuberculosis.
Tenderpoint assessment
The MTPS was performed by applying with a thumb 4 kg
of pressure to each of the 18 tender and 3 control points
(Fig 1A). The subject is asked to rate the tenderness expe-
rienced on a scale of 0 (no pain) to 10 (worst pain ever
experienced). The diagnosis of FM requires tenderness for
≥ 11 of the 18 points[7]. Because the MTPS does not
include the pelvis, we added an external pelvic tender
point scale (EPTPS) consisting of 10 tender points and an
internal pelvic tender point scale (IPTPS) consisting of
seven tender points including the prostate. (Fig. 1A, B and
1C). These pelvic points were determined based on the
clinical experience of one of the authors (R.B.). The EPTPS
included bilateral points over the pubic symphysis, mid-
inguinal canal, crura of the penis in the perineum, and the
adductor tendons at the attachment to the pelvis. Midline
points tested were suprapubically 4 cm above the symph-
ysis and over the bulbar urethra in the mid-perineum. The
IPTPS included bilateral points over the prostate midway
between the base and apex, the pubic symphysis and
endopelvic fasica on either side of and just lateral to the
prostate, and the lateral pelvic sidewalls over the levator
muscles. A single point midway between the rectum andPage 2 of 7
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MTPS tender point and control sites, EPTPS, and IPTPS,
the number of tender points was calculated and a severity
score was calculated by adding the individual ratings. Pro-
static scores (0–10) were taken from the left and right
prostate and added together (maximum of 20) for the
total prostatic score.
Each of the three examiners (two urologists and one nurse
practitioner; R.E.B, J.C.L., I.R.) practiced until he could
apply 4 ± .25 kg ten times in a row on a "Chatillon" dolo-
rimeter.(Amtek, Largo, FL.) Study participants were exam-
ined with the MTPS[7], then the EPTPS, then the IPTPS
and prostate. Each examiner recalibrated the force of his
finger at least weekly. Examiners 1, 2, and 3 examined 18,
32, and 48 control subjects, and 7, 33, and 22 pain
patients, based on logistical scheduling considerations.
A few pain patients and controls had missing tenderness
measure values for some points (but not all) because of
omissions in record keeping. The three examiners exam-
ined patients comparable in symptom severity according
to the NIH CPSI scores (p = 0.996, Kruskal-Wallis test).
Statistical analyses
Descriptive analysis was performed for all variables in the
study. Differences between pain patients and controls in
demographic characteristics were assessed by t-tests for
age and Chi-square tests for all other variables. Despite the
training protocol, there were some systematic differences
between examiners in tender point examination scores.
Given that the distributions of the tender point measures
were not normal, we used two complementary
approaches to examine differences between groups while
accounting for examiners. First, we dichotomized each
tenderness scale severity score (lower 10% of the possible
scores, highest 90% of possible scores; Table 1). We then
applied the method of Mantel-Haenszel to compare the
odds that a pain patient score is in the highest 90% of the
scale, to the odds of a control subject, while controlling
for the examiner. 19Second, we analyzed the original scale
of severity scores separately for each examiner using the
Mann-Whitney test to compare controls to pain patients.
This analysis was based on the premise that if there were
differences between controls and pain patients, the differ-
Table 1: Definition of the dichotomous transformation of the tender point examination scale severity scores
Dichotomous variable defined as
Scale Possible Range 0 if value in range 1 if value in range
MTPS Control 0–30 0–3 4–30
MTPS Tender points 0–180 0–18 19–180
EPTPS 0–100 0–10 11–100
IPTPS 0–50 0–5 6–50
Total Prostate Score 0–20 0–2 3–20
MTPS = myofascial tender point score, EPTPS = external pelvic tender point score, IPTPS = internal pelvic tender point score, Total Prostate Score 
= sum of scores of left and right prostate.
Diagram of pelvic tender points used in this studyFigure 1
Diagram of pelvic tender points used in this study. B) Ventral 
depiction of EPTPS points, C) Perineal view of EPTPS, 4) 
Horizontal view of IPTPS. Numbers represent ratio of 
patient to control number of positive tender points and 
therefore relative tenderness of patients over controls The 
red dots indicate the location of tender points. The points 
over the adductor insertions are represented on ventral and 
perineal depictions.Page 3 of 7
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by each examiner. Consistency in significant differences
would lead to the conclusion that the two groups of sub-
jects are different regarding the tenderness scales,
although we cannot specifically state the magnitude of
that difference across clinicians.
We calculated Spearman correlations to examine the asso-
ciation between the tenderpoint scores and the NIH CPSI.
Inflammation (defined by EPS leukocytes count) was
compared to tenderness (as defined in Table 1) by Chi-
square test.
Results
Seventy-two men with CP/CPPS and 98 controls were
enrolled as part of a larger study[11-16]. The tender points
examination was instituted after the first 10 CP/CPPS sub-
jects. Therefore, the present report is based on 62 CP/
CPPS subjects and 98 controls. Patients and controls dif-
fered significantly on age (p < 0.001), education (p <
0.001), and employment status (p = 0.02), but not on race
(p = 0.50) and marital status (p = 0.09) (Table 2). Among
the CP/CPPS patients, 40.3% were Type IIIA, 18.1% Type
IIIB, and 41.7% had undetermined type because EPS
could not be obtained. Among controls, 38.8% had leu-
kocyte counts > 500/mm3and 26.5% = 500/mm3, and EPS
was not obtained for 34.7%. Subjects who the examiner
was able to obtain EPS did not differ demographically
from those in whom the examiner was unable to obtain
EPS.
The proportion of subjects in the higher category of pain
level for each tenderness site is shown in Table 3. Except
for the control sites for tenderness, the pain group had
consistently larger proportions of subjects with high
scores than the control group. For example, 28.7% of the
controls and 67.3% of the pain patients had high scores
(as defined in Table 1) for IPTPS. Tenderness was found
on prostate examination in 28 of 94 (29.8%) controls and
31 of 54 (57.4%) CP/CPPS patients.
To study the difference in proportions adjusting for clini-
cians, the dichotomized variables (low versus high level of
pain) were analyzed using the Mantel-Haenzel method
(Table 4). Pain patients were more likely than control sub-
jects to be in the higher category of pain level for EPTPS,
IPTPS, and prostate severity scores (odds ratios = 9.59,
6.25, and 4.98; p < 0.0001 for all), but not for the control
site score (p = 0.98). There was a trend towards higher
odds of pain patients being in the higher pain category for
the MTPS tender points score (p = 0.069). When we exam-
ined dichotomized pain scores every point tested in the
pelvis was more often painful in CPPS patients than con-
trols except the suprapubic point. Relative ratios of pain-
Table 2: Sample Demographic Characteristics and NIH CPSI Scores
Pain Patients n = 62 Controls n = 98 P-value*
Age, years, mean (SD) 40.7 (10.4) 34.2 (10.4) < 0.001
Race
Caucasian (%)** 88.5 84.7 0.50
Marital Status, % **
Married/living with significant other 62.9 44.9 0.09
Divorced/separated 8.1 12.2
Never married 29.0 42.9
Education, %**
Some HS, HS/GED, or Vocational/Technical 18.3 3.1 < 0.001
Some college 6.7 28.6
College graduate 36.7 36.7
Graduate/professional school 38.3 31.6
Employment, %**
Full time work 72.1 55.7 0.02
Part-time work 8.2 18.6
School (full or part-time) 8.2 20.6
Retired, homemaker, unemployed 11.5 5.2
NIH Chronic Prostatitis Symptom Index***
Total Score, mean (SD) 21.8 (6.9) 0
Urinary Symptoms, mean (SD) 4.0 (2.8) 0
Pain, mean (SD) 10.1 (4.0) 0
Quality of Life, mean (SD) 7.6 (2.6) 0
* Difference in mean age was tested using t-test. All other differences were assessed by a Chi-square test.
**Information was not available on race for 1 pain patient, on education for 2 pain patients, and on employment for 1 pain patient and 1 control.
*** NIH CPSI data for pain patients were missing for 9 patients on the total score, 5 on the Urinary Symptoms scale, 8 on the Pain scale, and 5 on 
the Quality of Life scale. Control subjects were eligible for the study only if their NIH CPSI score was zero.Page 4 of 7
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mid perineum at 5.9. Most other ratios were 2–3. (Fig 1)
The second approach used the originally observed scores
without dichotomization. In comparisons of the median
scale scores of the patient and control groups for each
examiner, there were statistically significant differences
for all scales except the control sites (Table 5). For exam-
iner 1, there were no statistically significant differences,
although there were trends towards significant differences
on the IPTPS and prostate scales, most likely because this
clinician saw the smallest number of pain patients and
controls.
Additionally, Spearman correlation was calculated for the
tenderness points scores and the NIH CPSI for the pain
patients. All tender point scales were statistically signifi-
cant at 0.001 level, varying from estimated correlations of
r = 0.29 (IPTPS and Control) to 0.73 (IPTPS with prostate
score). The NIH CPSI Pain scale was correlated signifi-
cantly with the FM and EPTPS, but not the IPTPS or pros-
tate score suggesting that the CPSI pain score is more
related to external than internal tenderness. However,
plots of NIH CPSI versus each scale (graphs not shown
here), showed that the associations are not necessarily lin-
ear, and therefore, they have limited value in describing
the association between the variables.
EPS was obtained for 64 controls and 40 patients. Inflam-
mation was defined as having leukocyte counts > 500/
mm3 in the EPS sample. There was no association between
inflammation in EPS and the dichotomous prostatic ten-
derness (p = 0.42) or FM, IPTPS, and EPTPS dichotomous
variables (all p-values > 0.23).
Discussion
Prostatic tenderness has been described in men with pros-
tatitis and CP/CPPS and is considered to be a characteris-
tic of both CP/CPPS Type IIIA and IIIB[4]. However, the
findings of this study indicate that not all men with CP/
CPPS have prostate tenderness, and about 30% of men
without CP/CPPS have such tenderness. Tenderness in the
internal and external pelvis as well as extra-pelvic regions
in men with CP/CPPS has not been described. To our
knowledge, this is the first study that has demonstrated
that men with CP/CPPS have increased tenderness in FM
tender points and in specific internal and external non-
prostatic pelvic locations. For example, men with CP/
CPPS were 9.59 and 4.98 times more likely than men
without pelvic pain to have scores in the higher 90% of
the EPTPS and prostate scales, respectively. This suggests
that CP/CPPS Type III is a pan-pelvic pain syndrome and
that tenderness is not limited to the prostate. For each
point in the pelvis that we tested, the CPPS group had
more tenderness than the control group. Furthermore,
increased tenderness even extended outside of the pelvis
to FM points suggesting a systemic component. The labe-
ling of chronic pelvic pain in men as "prostatitis" may
well mislead both patients and physicians into thinking
that the syndrome has a more limited focus and etiology
than it actually may have[20].
The finding of increased tenderness in MTPS tender points
in men with CP/CPPS is in accord with findings of dif-
fusely increased tenderness in women with interstitial cys-
titis, a syndrome possibly related to CP/CPPS[9]. We
hypothesize that central and/or peripheral pain sensitiza-
tion in the pelvis may account for the diffuse symptoms
and tenderness found in pelvic pain syndromes[21-25].
We have previously shown that there is sensitization to
perineal heat sensation in some men with CP/
CPPS[12,26] and that men with CP/CPPS often have
abnormalities of pelvic and abdominal muscular function
and sensation [13]. The diffuse tenderness on pelvic
Table 4: Common Odds Ratio Estimates (Mantel-Haenszel Method) for Examiners in Dichotomized Tenderness Severity Scores, 
Controlling for Differences across examiners.
Scale Estimated Odds Ratio* Asymptotic 95% Confidence Interval P-value for Odds Ratio
MTPS Control 0.98 0.17 – 5.67 0.98
MTPS Tender points 2.64 0.93 – 7.51 0.069
EPTPS 9.59 3.40 – 27.06 < 0.001
IPTPS 6.25 2.87 – 13.61 < 0.001
Prostate Score 4.98 2.21 – 11.24 < 0.001
* Ratio of the odds that a case has a score in the highest 90% by the odds that a control has a score in the highest 90%.
Table 3: Proportion of high scores (according to definitions in 
Table 1) for control and pain subjects
Proportion of High Score (# missing)
Scale Controls (n = 98) Pain Patients (n = 62)
MTPS Control 5.1 (0) 3.2 (0)
MTPS Tender points 11.8 (5) 16.7 (2)
EPTPS 18.4 (11) 49.1 (7)
IPTPS 28.7 (4) 67.3 (7)
Prostate Score 29.8 (4) 57.4 (8)Page 5 of 7
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of mechanical sensitization to pressure with the develop-
ment of allodynia and hyperesthesia mediated via the
CNS. If prostatic inflammation was the source of prostatic
pain and the non-prostate pelvic tenderness was second-
ary to muscle guarding, we would have expected to find a
relationship of prostatic secretion inflammation to pros-
tatic and muscle tenderness. Since we found no such asso-
ciations, we hypothesize that prostatic and other pelvic
tenderness may both be related to an another more dom-
inant process such as central or peripheral neural sensiti-
zation and that inflammation in prostatic secretion may
be incidental.
Limitations of this study should be acknowledged. The
sample came from a university tertiary care population
and the study findings may not generalize to other popu-
lations. The control group was a convenience sample of
volunteers and could have selection bias. Controls were
younger, and although we found no relationship of ten-
derness scores to age, other unknown differences may
have contributed to the differences found between
patients and controls in examination findings. Further-
more, we did not assess test-retest stability of the tender
point examination scores, and there were interrater differ-
ences. The determination of tenderness is a standard part
of clinical examination, although variation from exam-
iner to examiner is well known clinically and experimen-
tally[5,6]. Although some of our examiners consistently
found more tenderness, each examiner separately found
more tenderness in CPPS patients in the areas examined.
Conclusion
We found that men with CP/CPPS have generalized inter-
nal and external pelvic tenderness. The pathophysiology
of CP/CPPS involves the entire pelvis and not only the
prostate. Our findings suggest that further research involv-
ing the assessment of intra-and extra-pelvic tender points
may prove fruitful in increasing scientific understanding
of, and developing more effective treatments for, male
chronic pelvic pain syndromes.
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